Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valproate + divalproex refers to the combination use of two closely related drugs: valproate (which describes several salt forms including valproic acid and sodium valproate) and divalproex (a coordinated compound of sodium valproate and valproic acid, also known as valproate semisodium). Both are antiepileptic and mood-stabilizing agents commonly prescribed for treatment of epilepsy, prevention of migraine, and management of bipolar disorder. Their mechanism includes increased availability of gamma-aminobutyric acid (GABA) in the brain, blockage of voltage-gated sodium channels, and inhibition of histone deacetylases. Both agents carry significant risks, especially teratogenicity and hepatotoxicity, and are contraindicated in pregnancy and pre-existing liver disease[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valproate + divalproex.